AUTHOR=Hao Dan-Li , Wang Ya-Jie , Yang Jia-Ying , Xie Ran , Jia Ling-Yu , Cheng Jin-Tang , Ma Hai , Tian Ji-Xiang , Guo Shan-Shan , Liu Ting , Sui Feng , Zhao Yu , Chen Yan-Jun , Zhao Qing-He TITLE=The Alleviation of LPS-Induced Murine Acute Lung Injury by GSH-Mediated PEGylated Artesunate Prodrugs JOURNAL=Frontiers in Pharmacology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.860492 DOI=10.3389/fphar.2022.860492 ISSN=1663-9812 ABSTRACT=
Acute lung injury (ALI) or its aggravated stage acute respiratory distress syndrome (ARDS) is a common severe clinical syndrome in intensive care unit, may lead to a life-threatening form of respiratory failure, resulting in high mortality up to 30–40% in most studies. Nanotechnology-mediated anti-inflammatory therapy is an emerging novel strategy for the treatment of ALI, has been demonstrated with unique advantages in solving the dilemma of ALI drug therapy. Artesunate (ART), a derivative of artemisinin, has been reported to have anti-inflammatory effects. Therefore, in the present study, we designed and synthesized PEGylated ART prodrugs and assessed whether ART prodrugs could attenuate lipopolysaccharide (LPS) induced ALI